Phase 2 Trial Update: Lutetium Lu 177 Dotatate Study Recruiting (NCT05691465)

A Phase 2 clinical trial update was recorded on October 7, 2026, for a study related to somatostatin pathway targeting. The trial, registered as NCT05691465, is titled "Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells." The study is currently listed with a status of recruiting. It is designated as a Phase 2 trial. The trial is evaluating a radiation-based treatment approach in patients with metastatic prostate cancer that has neuroendocrine cell characteristics. No outcome data, efficacy findings, or safety results have been reported as part of this update. The listing reflects only the current recruitment status and trial design information available as of the date noted. Somatostatin remains classified under unapproved research status, and this trial update does not change or confirm its regulatory standing. Readers should note that recruiting status indicates the trial is open for participant enrollment, not that any conclusions about the treatment have been reached. Further updates will depend on future postings to the trial registry. For additional background on somatostatin and its research context, readers can consult the compound overview.